HLA-C and myelodysplastic syndrome: In MDS patient samples, the compound increased CTA-specific CTL recognition of upregulated CTAs in bone marrow cells of MDS patients, along with enhanced CTL function and increased expression of major histocompatibility complex (MHC) class I and II proteins as well as ICAM-1 (a cell adhesion molecule that enhances binding with T cells for tumor lysis) (54).